PropThink: No Launch Yet for AMRN’s Vascepa is Good News; NCE Decision Is The Next Key Event

[ACN Newswire] – By David MoskowitzEarnings for Amarin Corp. (NASDAQ:AMRN) were primarily focused on the company’s strategy for the launch of Vascepa, as well as the FDA’s decision on whether the newly approved product … more

View todays social media effects on AMRN

View the latest stocks trending across Twitter. Click to view dashboard